NHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing

Size: px
Start display at page:

Download "NHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing"

Transcription

1 NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: Document history: Version Created by Date Main Changes/Comments 2 H Lucas R Brown Clarification of monitoring requirements and 8 week initial supply from hospital specialist. 4 H Lucas Amendments to patient responsibilities 5 H Lucas Addition of NICE criteria for treatment & specialist responsibility for at least 8 weeks stressed. 6 H Lucas Amendments to consultant responsibilities 2.2 act on results and GP responsibility 5 breathlessness added Date of Issue: Page 1 of 7

2 Shared Care Guideline Shared Care Guideline for prescribing Dronedarone (Multaq ) DRONEDARONE MUST BE INITIATED AND MANAGED BY THE HOSPITALSPECIALIST TEAM FOR AT LEAST THE FIRST 8 WEEKS OF THERAPY. This includes taking responsibility for issuing prescriptions for dronedarone and ensuring appropriate monitoring is undertaken. INDICATION Dronedarone (Multaq ) Dronedarone is an antiarrhythmic drug belonging to the benzofuran class of agents. It is licensed for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation. Due to its safety profile dronedarone should only be prescribed after alternative treatment options have been considered. Dronedarone should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure. In accordance with NICE TA 197 : Dronedarone is an option for the maintenance of sinus rhythm in patients with paroxysmal or permanent AND who have at least one of the following CV risk factors: o age 70 years or older o hypertension requiring drugs of at least two different classes o diabetes mellitus o previous TIA, stroke or systemic embolism o left atrial diameter of 50 mm or greater Please note that left ventricular systolic dysfunction or heart failure are now contraindications to treatment. AREAS OF RESPONSIBILITY FOR SHARED CARE This shared care agreement outlines suggested ways in which the responsibilities for managing the prescribing of dronedarone can be shared between the specialist and general practitioner (GP). Shared care must be agreed prior to the patient commencing treatment on dronedarone. GPs are invited to participate. If the GP is not confident to undertake these roles, then he or she is under no obligation to do so. In such an event, the total clinical responsibility for the patient for the diagnosed condition remains with the specialist. If a specialist asks the GP to prescribe this drug, the GP should reply to this request as soon as practicable. Date of Issue: Page 2 of 7

3 Sharing of care assumes communication between the specialist, GP and patient. The intention to share care is usually explained to the patient by the doctor initiating treatment. It is important that patients are consulted about treatment and are in agreement with it. The doctor who prescribes the medication legally assumes clinical responsibility for the drug and the consequences of its use. REFERRAL AND INITIATION Shared Care is only appropriate if it provides the optimum solution for the patient. Patients will only be referred to the GP once the GP has agreed in each individual case Management of atrial fibrillation should be consistent with NICE guidance. Dronedarone is a black triangle drug. The MHRA therefore asks that all suspected reactions (including those not considered to be serious) are reported through the Yellow Card Scheme. Date of Issue: Page 3 of 7

4 Specialist Responsibilities 1. Assess the patient and establish the diagnosis; determine a management strategy and whether the patient s GP will accept shared care prior to commencing dronedarone. If the GP does not accept shared care the total clinical responsibility for the patient for the diagnosed condition remains with the specialist. Ensure appropriate follow-up in conjunction with the GP. 2. To: 2.1. Initiate and stabilise treatment; 2.2. Perform Liver Function Tests (LFT s) prior to initiation, and one week and one month following initiation, and act on the results prior to transferring prescribing to the GP Measure plasma creatinine values prior to treatment and 7 (and possibly 14) days after initiation. To document and communicate to the GP the new reference baseline Monitor the patient and their therapy at six monthly intervals If the GP has accepted shared care, transfer prescribing to the GP once treatment has been stabilised (usually at 8 weeks) 3. Ensure patient is appropriately anticoagulated. 4. Stop treatment in patients with raised levels of the liver enzyme alanine aminotransferase (more than three times above the upper limit of normal) and closely observe the patients should continue until the enzyme levels return to normal. 5. Follow up ECG (if QTc Bazett interval greater than or equal to 500 milliseconds, dronedarone should be stopped). 6. To provide the GP with appropriate prescribing information and any additional information requested. 7. To be available for advice if the patient s condition changes. 8. To ensure that procedures are in place for the rapid re-referral of the patient by the GP. 9. To ensure the patient has given informed consent to their treatment. 10. To liaise with the GP on any suggested changes in prescribed therapy. 11. Patients should be warned to avoid drinking grapefruit juice beverages. 12. Review concurrent medication for potential interactions. Date of Issue: Page 4 of 7

5 General Practitioner Responsibilities 1. Initially, to refer the patient for specialist advice. 2. Where appropriate, to continue to prescribe dronedarone as part of a shared care arrangement (usually after 8 weeks). 3. Check LFT s monthly for 6 months and at month 9 and 12, and every 6 months thereafter. 4. Perform ECG every 6 months to check that patient has not developed permanent AF and to check ventricular heart rate (notify specialist if ventricular rate falls below 50bpm). Treatment discontinuation should be considered if a patient develops permanent AF. 5. Monitor patient every 6 months for signs or symptoms of heart failure that worsen or develop, such as weight gain, dependant oedema, or increased breathlessness. If heart failure develops or worsens consider suspending or discontinuing dronedarone. 6. Monitor renal function every 6 months. Discontinue treatment if further elevations in creatinine. 7. Monitor patient every 6 months for dyspnoea or non productive cough which may indicate the development of interstitial lung disease. 8. To deal with general health issues of the patient. 9. Monitor concordance with therapy. 10. Review concurrent medication for potential interactions Patient's role (or that of carer) 1. Report to the specialist or GP if he or she does not have a clear understanding of the treatment. 2. Attend appropriate GP and other follow up appointments. 3. Immediately report to their doctor any symptoms that could indicate liver injury (such as sustained new-onset abdominal pain, loss of appetite, nausea, vomiting, fever, fatigue, tiredness, yellowing of the skin or whites of the eyes, dark urine or itching). 4. Immediately report to their doctor any signs or symptoms of heart failure that worsen or develop, such as weight gain, swollen feet or legs, or increased shortness of breath. 5. Immediately report to their doctor any shortness of breath or non productive cough. 6. Share any concerns in relation to treatment with dronedarone. 7. Use written and other information on the medication. Date of Issue: Page 5 of 7

6 8. Seek help urgently if side effects are suspected, or is otherwise unwell. SUPPORTING INFORMATION Dosage and Administration Dronedarone (Multaq ) is available as a 400mg film coated tablet. The recommended dose of dronedarone is 400 mg twice daily in adults. One tablet with the morning meal and one tablet with the evening meal. Monitoring Liver Function tests Before starting treatment liver function tests should be performed. Tests should be repeated at month one and then monthly for six months, at months 9 and 12, and every 6 months thereafter. Treatments should be stopped in patients with raised levels of the liver enzyme alanine aminotransferase (more than three times above the upper limit of normal). Appropriate investigation and close observation of patients should continue until the enzyme levels return to normal. Plasma Creatinine Plasma creatinine values should be checked prior to initiation and 7 days after initiation. Any increase should be rechecked after a further 7 days. If the creatinine has stabilised this value is used as the new baseline. Cardiovascular Follow up ECG every 6 months is recommended during treatment. Treatment discontinuation should be considered if permanent AF develops. Monitor patient for any any signs or symptoms of heart failure that worsen or develop, such as weight gain, dependant oedema, or increased dyspnoea. Pulmonary Monitor patient for dyspnoea or non productive cough that may be related to pulmonary toxicity. Contraindications Hypersensitivity to the active substance or to any of the excipients Second or third degree Atrio-Ventricular block, complete bundle block, distal block,sinus node dysfunction, atrial defects or sick sinus syndrome (except when used in conjunction with a functioning pacemaker) Bradycardia<50 beats per minute Permanent AF with an AF duration > /= 6 months ( or duration unknown) and attempts to restore sinus rhythm no longer considered by the physician Patients in unstable hemodynamic conditions History of, or current heart failure or left ventricular systolic dysfunction Patients with liver and lung toxicity related to the previous use of amiodarone Co-administration with potent cytochrome P450 (CYP) 3A4 inhibitors, such as ketoconazole, itraconazole, voriconazole, posaconazole, telithromycin, clarithromycin, nefazodone and ritonavir Date of Issue: Page 6 of 7

7 Medicinal products inducing torsades de pointes such as phenothiazines, cisapride, bepridil, tricyclic antidepressants, terfenadine and certain oral macrolides, Class I and III antiarrhythmics QTc Bazett interval >/= 500milliseconds Severe hepatic impairment Severe renal impairment (CrCl<30ml/min) Special Warnings See manufacturer s SPC. Side Effects Very common: Congestive heart failure Common: blood creatinine increased; LFT abnormalities QTc Bazett prolonged; bradycardia; diarrhoea; vomiting, nausea, abdominal pains, dyspepsia, rashes (including generalised, macular, maculopapular), pruritus, fatique, asthenia. Drug Interactions Dronedarone is primarily metabolised by CYP3A4. Therefore inhibitors and inducers of CYP3A4 have the potential to interact on dronedarone. The following interactions are some of the more common that can occur: Digoxin; concomitant use will cause an increase in digoxin levels. It is recommended that the digoxin dose is halved. Grapefruit juice; significantly increases dronedarone exposure. Patients should not consume. Statins; concomitant use of statins should be undertaken with caution, lower starting and maintenance doses of statins should be considered. Beta blockers and calcium antagonists with depressant effect on sinus and AV node- concomitant use should be undertaken with caution. Warfarin; significant INR elevations have been observed after 1 week. Monitor INR closely. Dabigatran; dronedarone increases the exposure of dabigatran. Co-administration is not recommended.the manufacturer s summary of product characteristics (SPC) and the most current edition of the British National Formulary should be consulted for full information on contra-indications, warnings, sideeffects and drug interactions. At current prices the cost of one year s treatment with dronedarone 400mg bd is (BNF November 2010) References 1. Multaq 400mg tablets. Summary of Product Characteristics, Sanofi Aventis. October Drug Safety Update. October 2011;vol 5,issue 3: MHRA Date of Issue: Page 7 of 7

EFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation

EFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation EFFECTIVE SHARED CARE AGREEMENT Dronedarone - For the treatment and management of atrial fibrillation Specialist details Patient identifier Name INTRODUCTION This shared care agreement outlines how the

More information

EFFECTIVE SHARED CARE AGREEMENT. July Dronedarone (Multaq ) For the treatment and management of atrial fibrillation

EFFECTIVE SHARED CARE AGREEMENT. July Dronedarone (Multaq ) For the treatment and management of atrial fibrillation Whipps Cross University Hospital NHS Trust EFFECTIVE SHARED CARE AGREEMENT July 2011 Dronedarone (Multaq ) For the treatment and management of atrial fibrillation INTRODUCTION The Whipps Cross University

More information

PRESCRIBING ALERT

PRESCRIBING ALERT www.empr.com PRESCRIBING ALERT Dear Healthcare Professional, At MPR we strive to bring you important drug information in a concise and timely fashion. In keeping with this goal, we are pleased to bring

More information

ESCA: Cinacalcet (Mimpara )

ESCA: Cinacalcet (Mimpara ) ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details

More information

LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST

LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST AND LINCOLNSHIRE PARTNERSHIP FOUNDATION TRUST SHARED CARE GUIDELINE: Dronedarone for the treatment of

More information

. AREAS OF RESPONSIBILITY FOR SHARED CARE

. AREAS OF RESPONSIBILITY FOR SHARED CARE SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It

More information

Dronedarone for the treatment of non-permanent atrial fibrillation

Dronedarone for the treatment of non-permanent atrial fibrillation Dronedarone for the treatment of non-permanent atrial Issued: August 2010 last modified: December 2012 guidance.nice.org.uk/ta197 NICE has accredited the process used by the Centre for Health Technology

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the

More information

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance

More information

Dorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )

Dorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) INDICATION SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) Eplerenone is an aldosterone antagonist licensed to be used in addition to standard therapy including beta-blockers, to reduce the

More information

Shared Care Agreement for Donepezil

Shared Care Agreement for Donepezil ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE SHARED CARE PRESCRIBING GUIDELINE RILUZOLE for the Treatment of MOTOR NEURONE DISEASE NHS Surrey s Medicines Management Committee classification: Amber N.B. The eligibility criteria included here apply

More information

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE INDICATION By inhibiting metabolism of levodopa, entacapone or opicapone allow a reduction

More information

AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE

AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE Effective Shared Care Agreement (ESCA) Midodrine ESCA: For the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment

More information

Bournemouth, Dorset and Poole Prescribing Forum

Bournemouth, Dorset and Poole Prescribing Forum SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for

More information

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)

Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient

More information

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of dementia AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This

More information

Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:

Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date: Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to

More information

Shared Care Agreement for Donepezil, Galantamine, Rivastigmine and Memantine

Shared Care Agreement for Donepezil, Galantamine, Rivastigmine and Memantine Clinical SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: Date Treatment Started: Name of drug: (Add Date) One copy of information leaflet given to

More information

EFFECTIVE SHARED CARE AGREEMENT (ESCA)

EFFECTIVE SHARED CARE AGREEMENT (ESCA) WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic

More information

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable

More information

NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST

NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease

More information

dronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd

dronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd dronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd 6 August 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises

More information

Essential Shared Care Agreement Drugs for Dementia

Essential Shared Care Agreement Drugs for Dementia Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give

More information

Appendix IV - Prescribing Guidance for Apixaban

Appendix IV - Prescribing Guidance for Apixaban Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients

More information

BNSSG Shared Care Guidance Please complete all sections

BNSSG Shared Care Guidance Please complete all sections NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please

More information

Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression

Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:

More information

White, oblong shaped tablets, engraved with a double wave marking on one side and 4142 code on the other side.

White, oblong shaped tablets, engraved with a double wave marking on one side and 4142 code on the other side. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT MULTAQ 400 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 400 mg of dronedarone (as hydrochloride).

More information

National Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007

National Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007 Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not

More information

Amiodarone. Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers

Amiodarone. Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Amiodarone Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Licensed Indications Tachyarrhythmias associated with Wolff-Parkinson-White syndrome All types of tachyarrhythmias

More information

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP

GREATER MANCHESTER INTERFACE PRESCRIBING GROUP GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)

More information

Cardiff and Vale (C&V) UHB Corporate Medicines Management Group Shared Care Committee SHARED CARE

Cardiff and Vale (C&V) UHB Corporate Medicines Management Group Shared Care Committee SHARED CARE Cardiff and Vale (C&V) UHB Corporate Medicines Management Group Shared Care Committee SHARED CARE Drug: RILUZOLE Protocol number: CV 39 Indication: AMYOTROPHIC LATERAL SCLEROSIS (ALS) General Guidance

More information

Ivabradine for treating chronic heart failure: NICE technology appraisal guidance 267 Information for East Kent GPs revised July 2015

Ivabradine for treating chronic heart failure: NICE technology appraisal guidance 267 Information for East Kent GPs revised July 2015 Ivabradine for treating chronic heart failure: NICE technology appraisal guidance 267 Information for East Kent GPs revised July 2015 In November 2012 NICE recommended that: 1.1 Ivabradine is recommended

More information

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013

Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to

More information

Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures

Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,

More information

Information leaflet for primary care: Agomelatine

Information leaflet for primary care: Agomelatine Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin

More information

MULTAQ Prescribing Information February 2011 WARNING: HEART FAILURE

MULTAQ Prescribing Information February 2011 WARNING: HEART FAILURE MULTAQ Prescribing Information February 2011 WARNING: HEART FAILURE MULTAQ is contraindicated in patients with NYHA Class IV heart failure or NYHA Class II III heart failure with a recent decompensation

More information

SHARED CARE AGREEMENT: MELATONIN (CHILDREN)

SHARED CARE AGREEMENT: MELATONIN (CHILDREN) NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate

More information

Shared Care Guideline for Ranolazine in the Management of Stable Angina Pectoris

Shared Care Guideline for Ranolazine in the Management of Stable Angina Pectoris Shared Care Guideline for Ranolazine in the Management of Stable Angina Pectoris Introduction Indication/Licensing information Ranolazine (Ranexa), as recommended by NICE, is indicated in adults as add-on

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ (dronedarone)

More information

Review guidance for patients on long-term amiodarone treatment

Review guidance for patients on long-term amiodarone treatment Review guidance for patients on long-term amiodarone treatment This review guidance document has been produced in response to: 1. Current supply shortages of branded and generic versions of 100mg and 200mg

More information

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the

More information

Shared Care Guideline Metolazone for fluid management in CKD (Adults)

Shared Care Guideline Metolazone for fluid management in CKD (Adults) Shared Care Guideline Metolazone for fluid management in CKD (Adults) It is vital for safe and appropriate patient care that there is a clear understanding of where clinical and prescribing responsibility

More information

EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens

EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.

More information

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. Tivozanib. PROTOCOL REF: MPHATIVOUR (Version No: 1.

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. Tivozanib. PROTOCOL REF: MPHATIVOUR (Version No: 1. Systemic Anti Cancer Treatment Protocol Tivozanib PROTOCOL REF: MPHATIVOUR (Version No: 1.0) Approved for use in: Tivozanib is indicated for the first line treatment of advanced / metastatic renal cell

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT MULTAQ 400 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 400 mg of dronedarone (as

More information

Reference ID:

Reference ID: HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ (dronedarone)

More information

DRUG NAME: EDOXABAN (LIXIANA ) Transfer of Care document Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism

DRUG NAME: EDOXABAN (LIXIANA ) Transfer of Care document Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism

More information

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

Tacrolimus (Adoport, Prograf, Modigraf or Advagraf )

Tacrolimus (Adoport, Prograf, Modigraf or Advagraf ) Shared Care Guideline DRUG: Tacrolimus (Adoport, Prograf, Modigraf or Advagraf ) for Renal Transplant (Adults) Introduction: Indication: Prophylaxis of transplant rejection in kidney recipients Tacrolimus

More information

SULFASALAZINE (Adults)

SULFASALAZINE (Adults) Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn

More information

EFFECTIVE SHARE CARE AGREEMENT. For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP.

EFFECTIVE SHARE CARE AGREEMENT. For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP. Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of LIOTHYRONINE for patients registered with a Dudley GP. The aim of an Effective Shared Care Agreement

More information

2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate

2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team

More information

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC)

More information

Rivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.

Rivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg. Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist

More information

EFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY

EFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines

More information

AF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire

AF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that

More information

Treatment strategy decision tree

Treatment strategy decision tree strategy decision tree strategy decision tree Confirmed diagnosis of AF Further investigations and clinical assessment including risk stratification for stroke/thromboembolism Paroxysmal AF Persistent

More information

Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation

Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Rivaroxaban is a non-vitamin K antagonist oral anticoagulant

More information

INTRODUCTION Indication and Licensing

INTRODUCTION Indication and Licensing City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism

More information

Lapatinib and capecitabine for breast cancer Funding arrangements to be set up and specified locally Page 1 of 5

Lapatinib and capecitabine for breast cancer Funding arrangements to be set up and specified locally Page 1 of 5 Indication: Funding arrangements to be set up and specified locally Page 1 of 5 Lapatinib in combination with Capecitabine is recommended as a treatment option for people with advanced and/or metastatic

More information

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised

HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor

More information

Document Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers

Document Details Shared Care Agreement Lisdexamfetamine Trust Ref No Local Ref (optional) Main points the document covers Document Details Title Shared Care Agreement Lisdexamfetamine Trust Ref No 1989-33708 Local Ref (optional) Main points the document covers The responsibilities of each partner entering into the shared

More information

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism

Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral

More information

SHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS

SHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS SHARED CARE GUIDELINE ON THE USE OF FIASP FOR THE MANAGEMENT OF TYPE 1 DIABETES IN ADULTS INDICATION Fiasp is indicated for the treatment of diabetes mellitus in adults. Special Note: DMAG has approved

More information

Basingstoke,Winchester and Southampton District Prescribing Committee. Shared Care Guideline: Sirolimus

Basingstoke,Winchester and Southampton District Prescribing Committee. Shared Care Guideline: Sirolimus Basingstoke,Winchester and Southampton District Prescribing Committee Shared Care Guideline: Sirolimus Name of patient treated under this guideline: This shared care guideline has been produced to support

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance

More information

PRESCRIPTION PAD. The Newsletter of the Cumbria Area Prescribing Committee. February 2012 No. 18. Click here to find more. News from the MHRA

PRESCRIPTION PAD. The Newsletter of the Cumbria Area Prescribing Committee. February 2012 No. 18. Click here to find more. News from the MHRA PRESCRIPTION PAD The Newsletter of the Cumbria Area Prescribing Committee February 2012 No. 18 Click here to find more Clinical policy and Formulary news Lothian changes Targeted Medication Use Reviews

More information

1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of acamprosate.

1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of acamprosate. SHARED CARE GUIDELINE FOR ACAMPROSATE 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of

More information

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) MMCP05 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION

More information

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1

More information

Hydroxychloroquine (Adults)

Hydroxychloroquine (Adults) Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: Hydroxychloroquine (Adults) Indication: Rheumatoid arthritis and inflammatory osteoarthritis, discoid and systemic lupus erythematosus,

More information

Prescribing Framework for Galantamine in the Treatment and Management of Dementia

Prescribing Framework for Galantamine in the Treatment and Management of Dementia Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)

More information

Azathioprine Shared Care Guideline for GPs

Azathioprine Shared Care Guideline for GPs Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis

More information

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)

Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:

More information

Prescribing Framework for Naltrexone in Alcohol Relapse Prevention

Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient

More information

PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD)

PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) PRESCRIBING GUIDANCE TACROLIMUS for the treatment of INFLAMATORY BOWEL DISEASE (IBD) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of

More information

Essential Shared Care Agreement Naltrexone

Essential Shared Care Agreement Naltrexone In partnership with as part of Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. The patient s GP 2. Put one copy

More information

TREATMENT INTENT Disease modification- see European LeukemiaNet (ELN) 2013 guidelines for treatment goals.

TREATMENT INTENT Disease modification- see European LeukemiaNet (ELN) 2013 guidelines for treatment goals. BOSUTINIB INDICATION Licensed / NICE TA401 (BLUETEQ required) The treatment of adult patients with chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML)

More information

Guidelines for the Prescribing of Sacubitril / Valsartan

Guidelines for the Prescribing of Sacubitril / Valsartan Hull & East Riding Prescribing Committee Guidelines for the Prescribing of Sacubitril / Valsartan 1. BACKGROUND Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor, including both a neprilysin

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED

More information

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care

Prescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care

More information

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval

More information

DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING

DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS

More information

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS

Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...

More information

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency

Atrial Fibrillation. A guide for Southwark General Practice. Key Messages. Always work within your knowledge and competency Atrial Fibrillation A guide for Southwark General Practice Key Messages 1. Routinely offer pulse checks to patients at high risk of AF 2. Use the CHA 2 DS 2 VASc score to identify patients for anticoagulation

More information

Patient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019

Patient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history 31/07/17 V02

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop

More information

Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for

More information

Southern Trust Anticoagulant Team

Southern Trust Anticoagulant Team CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute

More information

Western Locality Shared care information ~ Azathioprine and Mercaptopurine

Western Locality Shared care information ~ Azathioprine and Mercaptopurine The following guidelines are currently under review. In the interim, the guidelines remain valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they

More information

MULTAQ (dronedarone) 400mg film coated tablets

MULTAQ (dronedarone) 400mg film coated tablets MULTAQ (dronedarone) 400mg film coated tablets WARNING: HEART FAILURE MULTAQ is contraindicated in patients with NYHA Class IV heart failure, or NYHA Class II - III heart failure with a recent decompensation

More information

Atrial Fibrillation Cases. Dr Paul Broadhurst Consultant Cardiologist

Atrial Fibrillation Cases. Dr Paul Broadhurst Consultant Cardiologist Atrial Fibrillation Cases Dr Paul Broadhurst Consultant Cardiologist November 2011 Mr TH age 72 Routine medical for hypertension check Denies any symptoms despite close questioning PMH: hypertension, MI,

More information

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04 Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: AZATHIOPRINE Protocol number: CV 04 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION LIVER

More information

Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF

Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Traffic light classification- Amber 2 specialist initiation / recommendation Information

More information

Duration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1

Duration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1 Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic

More information

Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:

Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%

More information